点击蓝字，关注我们
Med. 2024 Nov 8. IF: 12.8
DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer.
Huai-liang Wu, Yue Gong, Yun-xiao Ling, Si-yu Wu, Peng Ji, Qian Zhao, Li-Hua He, Zhi-Ming Shao, Yi-Zhou Jiang, Guang-yu Liu.
Fudan University Shanghai Cancer Center, Shanghai, China; Shanghai Medical College, Fudan University, Shanghai, China; Sun Yat-sen University Cancer Center, Guangzhou, China.
CONTEXT AND SIGNIFICANCE: Triple-negative breast cancer (TNBC) exhibits resistance to immunotherapy due to its heterogeneous metabolic characteristics. Deciphering the metabolic mechanisms regulating anticancer immunity will provide new insights into therapeutic strategies for TNBC. Wu et al. performed bioinformatics analysis using FUSCC TNBC multi-omics data and identified a key metabolic enzyme, dihydrodiol dehydrogenase (DHDH), which is correlated with low immune infiltration. They found that D-xylose supplementation in vivo promoted CD8+ T cell infiltration and the expression of cytotoxic markers and increased the sensitivity of DHDH-overexpressing tumors to immunotherapy. Therefore, these findings may provide theoretical support for incorporating D-xylose or a xylose-rich diet alongside immunotherapy in TNBC patients with high DHDH expression.
HIGHLIGHTS
DHDH is an upregulated enzyme in “cold tumors” of TNBC
DHDH promotes tumor growth via immune regulation mediated by its enzymatic activity
D-xylose promotes immune infiltration via upregulation of PSMB9
D-xylose supplementation potentiates the efficacy of immunotherapy in TNBC
BACKGROUND: Although the prognosis of triple-negative breast cancer (TNBC) has significantly improved in the era of immunotherapy, many TNBC patients are resistant to therapies, and their disease progresses rapidly. Deciphering the metabolic mechanisms regulating anticancer immunity will provide new insights into therapeutic strategies for TNBC.
METHODS: In this study, we performed bioinformatics analysis in our multi-omics TNBC database and identified that a metabolic enzyme, dihydrodiol dehydrogenase (DHDH), might promote the phenotype of “cold tumor” in TNBC. The biological function of DHDH was verified by in vitro and in vivo functional experiments, and the potential molecular mechanism of DHDH promoting TNBC immune escape was further explored.
FINDINGS: Mechanistically, DHDH mediated the synthesis and depletion of the substrate D-xylose and inhibited the activation of the proteasome subunit beta type 9 (PSMB9) and further induction of the immune response. We demonstrated that D-xylose supplementation could enhance the proliferation of CD8+ T cells and the expression of cytotoxic markers against cocultured DHDH-wild type (WT) cells. Consistently, D-xylose supplementation in vivo promoted CD8+ T cell infiltration and the expression of cytotoxic markers and increased the sensitivity of DHDH-overexpressing tumors to immune checkpoint blockade (ICB).
CONCLUSIONS: Our findings reveal that a D-xylose-regulated PSMB9-dependent pathway governs tumor-intrinsic immunogenicity and, hence, the sensitivity to ICB, which may provide approaches to promote the “cold-to-hot” transition in TNBC.
FUNDING: This study was funded by the National Key Research and Development Plan of China, Shanghai Science and Technology Commission, National Natural Science Foundation of China, and China Postdoctoral Science Foundation.
KEYWORDS: triple-negative breast cancer, dihydrodiol dehydrogenase, d-xylose, proteasome subunit beta type 9, immunotherapy
DOI: 10.1016/j.medj.2024.10.012
（来源：SIBCS）
声 明
凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。
